Exscientia — AI-driven drug design (Centaur Chemist, EVE patient-derived tumor screening), Oxford UK. Acquired by Recursion Pharmaceuticals (NASDAQ: RXRX) in November 2024; the combined company now operates under the Recursion brand and exscientia.ai redirects to recursion.com. The Exscientia GitHub org remains active, publishing open-source scientific Python packages (molflux, physicsml, abodybuilder3, biosimspace) for computational chemistry and structural biology.
No public commercial APIs or developer products — platform access was always delivered through collaborative drug-discovery agreements with pharma partners.